Nothing less than the opportunity for skin and joint efficacy data. For your patients, that's everything.

Nothing less than the opportunity for skin and joint efficacy data.
For your patients, that's everything.

DURABLE, RAPID & CLEAR

In Ps, most patients achieved co-primary endpoints of PASI 90 and sPGA 0/1 at Week 16, including response 4 weeks after 1st dose. Most patients who achieved PASI 90 at Week 16 maintained it at Week 52. PASI 100 was achieved by many patients at Week 16 and by a majority at Week 52.^1-3

VIEW Ps EFFICACY

POWERFUL JOINT SYMPTOM RELIEF

In PsA, a majority of patients achieved the primary endpoint of ACR20 at Week 24, experiencing improvement in joint symptoms including patient-reported pain data.¹

VIEW PsA EFFICACY

4 DOSES A YEAR

Reliable quarterly dosing after 2 initiation doses at
Weeks 0 and 4 (150 mg/injection) for Ps and PsA.¹

VIEW DOSING

PASI 90=≥90% improvement in Psoriasis Area and Severity Index; PASI 100=100% improvement in Psoriasis Area and Severity Index; sPGA 0/1=static Physician’s Global Assessment rating of clear or almost clear.

THE ONLY 4-DOSE-A-YEAR SYSTEMIC FOR PSORIASIS AND FOR PSORIATIC ARTHRITIS THAT OFFERS A SINGLE-DOSE PEN¹

FIND OUT MORE

Based on combined prescription data across
Ps and PsA, excluding generics and OTC

Source of data: Integrated Symphony Health as of 3/2024.⁴ The term branded systemic is defined as systemic drugs that are sold by a specific name or trademark and protected by patent. OTC stands for over-the-counter medications.

~99^%

PREFERRED* COMBINED NATIONAL COMMERCIAL AND MEDICARE PART D FORMULARY COVERAGE UNDER THE PHARMACY BENEFIT AS OF AUGUST 2025 IN Ps AND PsA^5†

VIEW ACCESS

*SKYRIZI is on a preferred tier or otherwise has preferred status on the plan’s formulary.
^†Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

THE ONLY Ps TREATMENT WITH
SUPERIORITY DATA ACROSS 5 MOAs^1,2,6-9

SKYRIZI VSOTEZLA® (apremilast)^6‡ PDE4 inhibitor

SKYRIZI VSSOTYKTU® (deucravacitinib)^7‡ TYK2 inhibitor

SKYRIZI VSCOSENTYX® (secukinumab)^8§ IL-17A inhibitor

SKYRIZI VSHUMIRA® (adalimumab)⁹ TNF inhibitor

SKYRIZI VSSTELARA® (ustekinumab)^1,2∥ IL-12 and IL-23 inhibitor

Click to see HUMIRA® (adalimumab)

Indication and Important Safety Information, including BOXED WARNING for Serious Infections and Malignancy. See

Full Prescribing Information

^‡Evaluated in patients with moderate plaque psoriasis eligible for systemic therapy.

^§SOURCING: In this study, 46 patients outside of the US received non–US-licensed secukinumab. Data regarding comparability between US and non-US secukinumab are not publicly available.¹⁰

^∥ACTIVE COMPARATOR: The ustekinumab used as a biologic active control in UltIMMa-1 and UltIMMa-2 was sourced from the European Union. Comparability between non–US-approved ustekinumab and US-approved ustekinumab has not been established.

Products and their designs are trademarks of their respective owners.

5 MOAs refers only to agents listed.

At week 16^1,2: 75% of Skyrizi patients (n=220/294) achieved pasi 90 in the UltIMMa-2 study vs 2% of placebo patients (n=2/98);

84% of SKYRIZI patients achieved sPGA 0/1 vs 5% of placebo patients

UltlMMa-1 results at Week 16
PASI 90: SKYRIZI 75% (n=304), placebo 5% (n=102)
sPGA 0/1: SKYRIZI 88% (n=304), placebo 8% (n=102)

Co-primary endpoints for UltIMMa-1 and -2 were PASI 90 and sPGA 0/1 response vs placebo at Week 16.

p<0.0001 for comparisons of SKYRIZI vs placebo

STUDY DESIGN:

UltIMMa-1 (N=506) and UltIMMa-2 (N=491) were replicate Phase 3, randomized, double-blind, placebo- and active-controlled studies to evaluate the efficacy and safety of SKYRIZI (150 mg) vs placebo over 16 weeks and biologic active control (45 mg or 90 mg, based on screening weight) over 52 weeks in adult patients with moderate to severe plaque psoriasis.^1,2

SEE CLINICAL TRIAL RESULTS INCLUDING PASI 100 DATA

At week 52^1,2: 81% of Skyrizi patients (n=237/294) achieved pasi 90 in the UltIMMa-2 study; placebo did not continue beyond Week 16

UltlMMa-1 results at Week 52
PASI 90: SKYRIZI 82% (n=249/304), placebo n/a

Co-primary endpoints for UltIMMa-1 and -2 were PASI 90 and sPGA 0/1 response vs placebo at Week 16.

p<0.0001 for comparisons of SKYRIZI vs placebo

STUDY DESIGN:

SEE CLINICAL TRIAL RESULTS INCLUDING PASI 100 DATA

Explore Long-term data

SKYRIZI has long-term efficacy data in Ps (~6 years) and PsA (~4 years) and long-term safety data (~9 years in Ps, 5 years in PsA)^11-14

Ps EFFICACY

PsA EFFICACY

SAFETY

4 doses
per year¹

3-month dosing after 2
initiation
doses at
Weeks 0 and 4 (150 mg/dose)

VIEW DOSING SCHEDULE

FOR BIOCOORDINATORS & OFFICE STAFF

Complete Pro is a flexible and easy-to-use portal designed to streamline and manage the prescription process to help patients start and stay on track with their prescribed treatment.

LEARN MORE ABOUT COMPLETE PRO

PREFERRED^¶ COVERAGE FOR ~99% OF COMMERCIAL Ps AND PsA PAYER LIVES^5#

National commercial formulary coverage under the pharmacy benefit as of August 2025

Eligible patients may be able to access their SKYRIZI at no charge until their insurance plan covers SKYRIZI or up to 2 years, whichever occurs earlier.^**

VIEW SKYRIZI COMPLETE

^¶SKYRIZI is on a preferred tier or otherwise has preferred status on the plan’s formulary.

^#Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

^**Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for SKYRIZI® (risankizumab-rzaa) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for SKYRIZI® (risankizumab-rzaa) at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.

THE ONLY Ps TREATMENT WITH
SUPERIORITY DATA ACROSS 5 MOAs^1,2,6-9

FOR BIOCOORDINATORS & OFFICE STAFF

PREFERRED^¶ COVERAGE FOR ~99% OF COMMERCIAL Ps AND PsA PAYER LIVES^5#

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

Indications

Important Safety Information

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

Indications

Important Safety Information

THE ONLY Ps TREATMENT WITH SUPERIORITY DATA ACROSS 5 MOAs1,2,6-9

FOR BIOCOORDINATORS & OFFICE STAFF

PREFERRED¶ COVERAGE FOR ~99% OF COMMERCIAL Ps AND PsA PAYER LIVES5#

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

Indications

Important Safety Information

STUDY DESIGN – IMMvent9

SELECTED BASELINE CHARACTERISTICS9,14

STUDY DESIGN—IMMhance1,10

SELECTED BASELINE CHARACTERISTICS10

STUDY DESIGN — UltIMMa-1 and UltIMMa-21,2

SELECTED BASELINE CHARACTERISTICS1

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

Indications

Important Safety Information

THE ONLY Ps TREATMENT WITH
SUPERIORITY DATA ACROSS 5 MOAs^1,2,6-9

PREFERRED^¶ COVERAGE FOR ~99% OF COMMERCIAL Ps AND PsA PAYER LIVES^5#

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

STUDY DESIGN – IMMvent⁹

SELECTED BASELINE CHARACTERISTICS^9,14

STUDY DESIGN—IMMhance^1,10

SELECTED BASELINE CHARACTERISTICS¹⁰

STUDY DESIGN — UltIMMa-1 and UltIMMa-2^1,2

SELECTED BASELINE CHARACTERISTICS¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹